Background: Wheeze and chest tightness has traditionally been associated with enhanced bronchial responsiveness. However, no community studies are available on the associations between bronchodilator response and respiratory symptoms among adults. Aim: To examine how respiratory symptoms predict bronchodilator response. Methods: An age and gender stratified random sample of all adults aged 47-48 and 71-73 years in Bergen, Norway, were invited. The 3506 participants (69%) filled in questionnaires including nine symptoms and performed bronchodilator reversibility tests. Subjects without current anti-asthmatic medication performing acceptable reversibility tests were included in the analyses ðn ¼ 3088Þ.
Introduction
Although asthma and chronic obstructive pulmonary disease (COPD) are diagnosed on the basis of airflow variability and limitation, 1-3 a patient normally decides to seek medical help because of unpleasant and impairing respiratory symptoms. COPD typically presents with chronic cough, phlegm and/or functional dyspnoea. The asthma phenotype has been characterised by wheezing, attacks of dyspnoea and chest tightness. Increased bronchodilator responsiveness is used both as a diagnostic criterion 1 and as an inclusion criterion to clinical trials on asthma. [4] [5] [6] Various cut-off levels defining abnormal forced expiratory volume in one second (FEV 1 ) responsiveness to b 2 -agonists have been suggested by international respiratory societies, such as the recent American Thoracic Society/European Respiratory Society (ATS/ERS) criterion of 200 ml and 12% initial. 7 In a recent Australian study, 8 1% to nearly 5% of adults in the community without a previous diagnosis of asthma had positive reversibility tests. These subjects were symptomatic, which had considerable consequences for their respiratory health. Nevertheless, no community-based data is available as to what extent respiratory symptoms predict bronchodilator responsiveness. This knowledge could support the physician's decision on whether bronchodilator reversibility tests should be performed based on the patient's symptoms.
Thus, the study objectives were to determine the prevalence of positive bronchodilator reversibility tests using internationally agreed cut-off values and to examine which of the respiratory symptoms that predicts an increased bronchodilator response among middle-aged and elderly in a general population.
Methods

Population and measurements
An age and gender stratified random sample of 5099 subjects were invited from two cohorts aged 47-48 years and 71-73 years living in Bergen, Norway, as part of an epidemiological follow-up study of cardiovascular health in 1998 (the Hordaland Health Study). 9 The attendants completed a questionnaire and performed bronchodilator reversibility tests. The questionnaire elicited information on respiratory symptoms, as well as smoking 10 and current use of anti-asthmatic medication (wording in the Appendix). Seven questions on symptoms, Q1, Q4, Q4.1, Q4.2, Q5-Q7, were taken from the International Union Against Tuberculosis and Lung Disease (IUATLD) questionnaire. 11, 12 The two questions (Q2, Q3) from the Norwegian Respiratory Questionnaire have been validated against lung function and bronchial reactivity 13 and compared with the British Medical Research Council questionnaire on chronic bronchitis. 14, 15 Bronchodilator reversibility tests were performed selecting the largest FEV 1 and forced vital capacity (FVC) from any of three acceptable and repeatable spirograms, 16 before and 15 min after inhalation of 400 mg salbutamol from a Discus inhaler. The bronchodilator response was expressed as 17 : the absolute response (post-salbutamol FEV 1 -initial FEV 1 ) ml, and the ''% initial'' index ((post-salbutamol FEV 1 -initial FEV 1 )/initial FEV 1 ) Â100. A positive response was defined as an FEV 1 increase of X12% initial and X200 ml. 7 Demographic details on the attendants, description of spirometry quality control procedures, and the reversibility test performance have been published previously. 18 Predicted values of FEV 1 were estimated using regression equations from a Norwegian reference population. 19 The Regional Ethics Committee has approved the study protocol and all attendants have given a fully informed consent to participate.
Statistical analyses
Descriptive statistics based on percentages for categorical data, means and standard deviations (SD) for quantitative variables were used, unless otherwise stated. Univariate analysis employed the two-sided Fisher's test for categorical variables and the unpaired t-test for quantitative variables. The Mann-Whitney test was used to compare means between groups with outcome variables deviating from normal distribution. Multiple linear regression analysis performed as a backward stepwise procedure was used to evaluate the relationship between respiratory symptoms and the bronchodilator response. Similarly, multiple logistic regression analyses were used to examine associations between symptoms and the ATS/ERS 7 response criterion. All regression analyses were adjusted for age-cohort, gender, height, body mass index (BMI), smoking status (current, ex, or never) and pack-years, and age and gender were kept in the final model even if not statistically significant. Interaction effects for pairs of symptoms, age, and gender were estimated. A two-sided p-value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS. 20
Results
Participation, demographics, and respiratory symptoms
The participation rate was higher in the middle-aged (76%) than in the elderly (64%) cohort ðp ¼ 0:0001Þ. Among the 3305 subjects who performed acceptable reversibility tests (94% of all participants), 53% of the women and 74% of the men were ever-smokers (Table 1) .
Altogether 83% of the middle-aged and 70% of the elderly were considered having normal lung function, the prebronchodilator FEV 1 in % predicted being X80% and the FEV 1 /FVC ratio being X0:7. Women reported ''dyspnoea climbing two stairs'' and ''woken by chest tightness'' more than men did; (24% vs. 17%, p ¼ 0:001) and (9% vs. 7%, p ¼ 0:011), respectively. Ever-smokers had a higher prevalence for all respiratory symptoms compared with never smokers ðpo0:05Þ, except for ''woken by chest tightness'', ''woken by attacks of breathlessness'', and ''asthma attack''. A total of 217 subjects (7%) were currently using anti-asthmatic medication.
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Prevalence of bronchodilator response
The frequency distribution at different cut-off points above 200 ml and the average bronchodilator response in the four age-gender groups are shown in Fig. 1 . The responses were small for both cohorts as the overall prevalence of subjects having an FEV 1 increase above 200 and 400 ml was 8.3% and 0.6%, respectively. The prevalence of FEV 1 increase X12% and 200 ml from initial spirometry (ATS/ERS criterion 7 ) was 2% in the middle-aged and 5% in the elderly ðp ¼ 0:001Þ. No responder differences were found by gender. Positive tests were found in 86 out of 3088 subjects (2% of middle-aged and 4% of the elderly, p ¼ 0:001) using the ATS/ERS criterion after exclusion of people with current anti-asthmatic medication ðn ¼ 217Þ. A total of 37 subjects (43%) of the reversibility test positive subjects had pre-bronchodilator FEV 1 /FVC ratio values below lower level of normal (LLN), using recently published Norwegian reference values 21 from the same study area.
Respiratory symptoms as predictors of bronchodilator response
Univariate analyses Elderly subjects reporting ''wheezing'', ''wheezing without cold'', and ''asthma attack'' and middle-aged reporting ''breathless when wheezing'' and ''woken by chest tightness'' had larger bronchodilator responses than those negative for these questions (Fig. 2) .
Subjects reporting respiratory symptoms had larger responses than asymptomatic subjects measured by the ''% initial'' index ( Fig. 3 ). In the elderly the response increased gradually by the number of symptoms to a plateau at three reported symptoms. Among middle-aged, however, only those reporting at least four symptoms had significantly larger response than the asymptomatic group ( Fig. 3) . No relationship was found between number of symptoms and bronchodilator response in either of the cohorts when using the absolute response (ml) as outcome variable.
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Multivariate analyses
In multiple linear regression analyses ''wheezing without cold'' and ''dyspnoea climbing two stairs'' predicted both indices of bronchodilatation positively (Table 2) , and the association between ''wheezing without cold'' and the absolute response (ml) was present in men only. ''Chronic cough'' predicted both response indices negatively. Applying multiple logistic regression analysis, solely ''morning cough'' was associated with a positive bronchodilator test using the ATS/ERS criterion of X12% initial and X200 ml (OR: 1.8, 95% CI: ð1:1; 2:8Þ, p ¼ 0:01).
The number of respiratory symptoms (0-7) predicted the ''% initial'' index (b ¼ 0:3, 95%CI: ð0:1; 0:4Þ, p ¼ 0:001) after adjustment for age-cohort and gender, but was not associated with the ''absolute response'' index in linear analysis. Similarly in categorical analysis, the increase in number of symptoms by one predicted the criterion of X12% initial and X200 ml by OR: 1.2, 95% CI: ð1:0; 1:4Þ, p ¼ 0:02.
Discussion
In this community study, less than 3% of middle-aged and elderly without current anti-asthmatic medication were classified as b 2 -agonist responders using the ATS/ERS criterion (FEV 1 increase of at least 200 ml and 12% initial). 7 Measuring the bronchodilator response at continuous scales, the asthma-like symptom ''wheezing without cold'' Mean AE SE of FEV 1 bronchodilator response (% from initial) after inhalation of 400 mg salbutamol by presence of maximum seven self-reported respiratory symptoms in middle-aged and elderly. Frequency of subjects in each symptom number category is written below the columns. Differences in bronchodilator response are assessed by Students t-test for each symptom number category, using the asymptomatic category as reference group; ns ¼ non-significant ðp40:05Þ; Ã pp0:05; ÃÃ pp0:01:
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predicted the absolute response (ml) positively in men and the ''% initial'' index in all subjects. ''Dyspnoea climbing two flights of stairs'' predicted both indices positively, while ''chronic cough'' was associated with a negative response. ''Morning cough'' was the only symptom independently predicting the ATS/ERS criterion. 7 This is the first study assessing the relationships between individual respiratory symptoms and the bronchodilator response to an inhaled b 2 -adrenoceptor agonist measured in adults from a general population. The strengths of the study are a large sample and a high response rate, allowing for precision in estimates. One well-trained technician guided all procedures, eliminating between-operator measurement variation.
The prevalence of bronchodilator response in the present study is largely in agreement with an Australian community study of people above 18 years. 8 The overall prevalence of achieving the reversibility criterion of X12% after inhaling 400 mg salbutamol was 3.8%, compared to 4.1% in the current study. The percentage achieving the BTS/NICE criterion of at least 400 ml, 1 however, was 2.0 (SE 0.22)% in the Australian study and 0.6 (SE 0.13)% in the current study, and the difference is probably due to the large fraction of younger adults in the former study.
The IUATLD respiratory symptom questionnaire, applied in the many European Community Respiratory Health Study (ECRHS) studies, 11, 22, 23 has to our knowledge never been evaluated in terms of its relation to a bronchodilator reversibility response, but has been extensively validated by airway hyperresponsiveness to histamine and methacholine. 12, 24 Combinations of wheezing, chest tightness, and asthma attacks have been advocated as the asthma syndrome. 25 Bronchoconstrictor and bronchodilator responsiveness are, however, different phenotypic markers that are not interchangeable. 26, 27 Nevertheless, we have con-firmed the association between adrenergic bronchodilator response and ''wheezing without cold''. The relationship between ''wheezing without cold'' and the absolute bronchodilator response differed significantly between men and women, also after taking the absolute postbronchodilator FEV 1 value (lung size) into account (results not shown). A previous community study has shown that men perceive respiratory symptoms at a more severe stage of bronchoconstriction compared to women, which might explain why men are more responsive to bronchodilators when reporting asthma-like symptoms. 28 This gender specific difference in symptom perception might be due to higher levels of anxiety and depression in women than men with airflow obstruction, as recently described in COPD patients. 29 Our data also suggest that chest wheezing present without having a cold is a more asthma specific question than the widely used, general question on ''wheezing the last 12 months''. This finding seems biologically plausible. Those reporting wheezing probably represent a mixture of subjects suffering from a variety of conditions. Obesity causing airway narrowing, 30 infections producing oedema and mucus, congestive heart failure with excessive interstitial fluid compressing the small airways, and obstructive lung disease with bronchial smooth muscle constriction are all disorders resulting in turbulent, noisy airflow. Thus, adding the question on wheezing excluding a common cold eliminate those reporting the symptom solely on the basis of simple viral airway infections.
Although to a lesser extent than ''wheezing without cold'', ''dyspnoea climbing two flights of stairs'' was associated with an increased bronchodilator response. Dyspnoea on exertion is a cardinal feature of obstructive lung disease and, compared to placebo, salbutamol inhalation has been shown to relieve breathlessness on exercise both by increasing FEV 1 and reducing dynamic hyperinflation Table 2 Respiratory symptoms predicting the FEV 1 absolute bronchodilator response (ml) and the change in % initial after inhalation of 400 mg salbutamol in middle-aged and elderly from a general population ðN ¼ 3088Þ.
Predictors of bronchodilator response
Absolute Multivariate linear regression analysis examining nine respiratory symptoms (Appendix), age-cohort, gender, height, body mass index, and smoking history (current, ex-or never smokers and packyears) as potential predictors of bronchodilator response. Variables with p40:05 were removed in a backward stepwise procedure with the exception of age-cohort and gender. Interaction analyses were performed for pairs of respiratory symptoms, age and gender, and terms with pp0:05 were introduced in a stepwise forward procedure and kept in the model if statistically significant. Subjects performing an unacceptable reversibility test ðn ¼ 201Þ and subjects on current anti-asthmatic medication ðn ¼ 217Þ were excluded from the multivariate analyses.
in patients. 31 Hence, the positive relationship between functional dyspnoea and bronchodilator responsiveness in the community was as expected.
The negative associations between chronic cough and both response indices, however, are more difficult to explain. One might speculate that excess mucus production in the bronchi, which covers the airway surface in subjects with chronic cough, 32 leads to an impaired access of salbutamol to the b 2receptors on smooth muscle cells. Peribronchiolar fibrosis is also commonly seen in chronic cough, 33 causing a fixed airflow obstruction in small airways. These findings should, however, be confirmed in future studies.
The symptoms of asthma attack and nocturnal chest tightness did not predict the response to salbutamol. Possibly, episodes of breathlessness caused by other diseases like angina pectoris, heart failure, obesity, panic disorders, and COPD may be perceived as attacks of asthma in the Norwegian population.
Although non-predictive of bronchodilator response measured on continuous scales, morning cough was the only symptom associated with positive test results following the ATS/ERS 7 criterion. These subjects may, at least partly, represent a phenotype of asthmatics recognised as ''cough variant asthma'', a clinical condition previously characterised by predominance of coughing without wheezing, normal baseline spirometry, and evidence of bronchial hyperreactivity to methacholine challenge tests. 34 This hypothesis is supported by the fact that all 17 subjects with morning cough and no wheeze had normal post-bronchodilator FEV 1 /FVC ratio ð40:7Þ among those positive for the ATS/ERS 7 reversibility criterion.
Positive reversibility tests have been a prerequisite for inclusion of subjects into a majority of clinical trials on antiasthmatic medications, 4-6 irrespective of the pre-bronchodilator level of lung function. Nevertheless, the current role of bronchodilator reversibility testing in subjects with normal spirometry is unclear. However, a large Australian community study 8 performing bronchodilator tests in all attendants has shown that the symptom burden is worse in test positive (4400 ml increase in FEV 1 ) 1 than test negative persons, even though known asthmatics were excluded. Importantly, the mean pre-bronchodilator FEV 1 in test positive subjects was within normal limits. In an Italian study 35 of 291 asthmatics with normal baseline spirometry 25% had an FEV 1 increase X12% after inhalation of 200 mcg salbutamol. Hence, data from both patient and general populations suggest that a large fraction of cases with reversible bronchial obstruction may be found among subjects without demonstrable airflow limitation on simple spirometry. The prognostic role of positive bronchodilator reversibility tests in subjects with normal spirometry should be established in future longitudinal community studies.
Our study shows that only a small fraction of middle-aged and elderly without current anti-asthmatic treatment in the community produce positive bronchodilator tests according to the recently published ATS/ERS criterion. From among nine commonly reported respiratory symptoms, positive answers to questions on chest wheezing without having a cold, dyspnoea climbing two flights of stairs, or morning cough predict the acute response to inhaled b 2 -adrenoceptor agonists. This study provides support for including these symptom questions when aiming to detect adults with salbutamol reversible airflow obstruction. Positive answers to these questions could also be used as one out of several indicators for b 2 -adrenergic bronchodilator reversibility testing.
